Decreased MicroRNA MiR-181c Expression in Peripheral Blood Mononuclear Cells Correlates with Elevated Serum Levels of IL-7 and IL-17 in Patients with Myasthenia Gravis

Overview

Journal Clin Exp Med

Specialty General Medicine

Date 2015 May 13

PMID 25962782

Citations 17

Authors

Yong Zhang

Mingfeng Guo

Ning Xin

Zhen Shao

Xiuying Zhang

Yanyan Zhang

Jing Chen

Shuangshuang Zheng

Linlin Fu

Yuzhong Wang

Dongmei Zhou

Hao Chen

Yan Huang

Ruiguo Dong

Chenghua Xiao

Yonghai Liu

Deqin Geng

Affiliations

Soon will be listed here.

Abstract

miR-181c is a newly identified negative regulator of immune cell activation. In this study, we aimed to investigate the expression and functional role of miR-181c in myasthenia gravis (MG). miR-181c showed significant downregulation in peripheral blood mononuclear cells (PBMCs) from MG patients compared with healthy controls, with lower expression in generalized patients than in ocular ones. MG patients also had increased serum IL-7 and IL-17 levels. Additionally, serum IL-7 level presents a positive correlation with the serum IL-17 level. miR-181c levels were negatively correlated with serum levels of IL-7 and IL-17 in either generalized patients or ocular patients. A luciferase reporter assay revealed that miR-181c could directly bind to the 3'-UTR of interleukin-7. Forced expression of miR-181c led to decreased IL-7 and IL-17 release in cultured PBMCs, while depletion of miR-181c increased the secretion of these two proinflammatory cytokines. The results from our study suggested for the first time that miR-181c was able to negatively regulate the production of proinflammatory cytokines IL-7 and IL-17 in MG patients, and it is a novel potential therapeutic target for MG.

Citing Articles

Non-Coding RNAs in Myasthenia Gravis: From Immune Regulation to Personalized Medicine.

Iacomino N, Tarasco M, Berni A, Ronchi J, Mantegazza R, Cavalcante P Cells. 2024; 13(18.

PMID: 39329732 PMC: 11430632. DOI: 10.3390/cells13181550.

Non-coding RNA and its network in the pathogenesis of Myasthenia Gravis.

Wang F, Mei X, Yang Y, Zhang H, Li Z, Zhu L Front Mol Biosci. 2024; 11:1388476.

PMID: 39318549 PMC: 11420011. DOI: 10.3389/fmolb.2024.1388476.

The intricate dance of non-coding RNAs in myasthenia gravis pathogenesis and treatment.

Wang B, Zhu Y, Liu D, Hu C, Zhu R Front Immunol. 2024; 15:1342213.

PMID: 38605954 PMC: 11007667. DOI: 10.3389/fimmu.2024.1342213.

Circulating miRNAs drive personalized medicine based on subgroup classification in myasthenia gravis patients.

Huang X, Zhang Z, Wang Y, Xu M, Du X, Zhang Y Neurol Sci. 2023; 44(11):3877-3884.

PMID: 37402938 DOI: 10.1007/s10072-023-06933-3.

LncRNA OIP5-AS1 modulates the proliferation and apoptosis of Jurkat cells by sponging miR-181c-5p to regulate IL-7 expression in myasthenia gravis.

Wang X, Zhang H, Lu X, Li S, Kong X, Liu L PeerJ. 2022; 10:e13454.

PMID: 35602889 PMC: 9121865. DOI: 10.7717/peerj.13454.

References

Meriggioli M, Sanders D . Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009; 8(5):475-90. PMC: 2730933. DOI: 10.1016/S1474-4422(09)70063-8. View

Fry T, Mackall C . The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance. J Immunol. 2005; 174(11):6571-6. DOI: 10.4049/jimmunol.174.11.6571. View

Hofer J, Hofer S, Zlamy M, Jeller V, Koppelstaetter C, Brandstatter A . Elevated proportions of recent thymic emigrants in children and adolescents with type 1 diabetes. Rejuvenation Res. 2009; 12(5):311-20. DOI: 10.1089/rej.2009.0863. View

Yang Y, Xiao X, Li F, Du L, Kijlstra A, Yang P . Increased IL-7 expression in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci. 2012; 53(2):1012-7. DOI: 10.1167/iovs.11-8505. View

Ma X, Zhou J, Zhong Y, Jiang L, Mu P, Li Y . Expression, regulation and function of microRNAs in multiple sclerosis. Int J Med Sci. 2014; 11(8):810-8. PMC: 4057480. DOI: 10.7150/ijms.8647. View

Xue Q, Guo Z, Li W, Wen W, Meng Y, Jia L . Human activated CD4(+) T lymphocytes increase IL-2 expression by downregulating microRNA-181c. Mol Immunol. 2010; 48(4):592-9. DOI: 10.1016/j.molimm.2010.10.021. View

Totsuka T, Kanai T, Nemoto Y, Makita S, Okamoto R, Tsuchiya K . IL-7 Is essential for the development and the persistence of chronic colitis. J Immunol. 2007; 178(8):4737-48. DOI: 10.4049/jimmunol.178.8.4737. View

Hartgring S, Bijlsma J, Lafeber F, van Roon J . Interleukin-7 induced immunopathology in arthritis. Ann Rheum Dis. 2006; 65 Suppl 3:iii69-74. PMC: 1798384. DOI: 10.1136/ard.2006.058479. View

Zheng S, Dou C, Xin N, Wang J, Li P, Fu L . Expression of interleukin-22 in myasthenia gravis. Scand J Immunol. 2013; 78(1):98-107. DOI: 10.1111/sji.12057. View

10.

OSSERMAN K, GENKINS G . Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. Mt Sinai J Med. 1971; 38(6):497-537. View

11.

Roche J, Capablo J, Larrad L, Gervas-Arruga J, Ara J, Sanchez A . Increased serum interleukin-17 levels in patients with myasthenia gravis. Muscle Nerve. 2011; 44(2):278-80. DOI: 10.1002/mus.22070. View

12.

Poussin M, Goluszko E, David C, Franco J, Christadoss P . HLA-DQ6 transgenic mice resistance to experimental autoimmune myasthenia gravis is linked to reduced acetylcholine receptor-specific IFN-gamma, IL-2 and IL-10 production. J Autoimmun. 2001; 17(3):175-80. DOI: 10.1006/jaut.2001.0541. View

13.

Mackall C, Fry T, Gress R . Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol. 2011; 11(5):330-42. PMC: 7351348. DOI: 10.1038/nri2970. View

14.

Hu X, Cao Y, Meng Y, Hou M . A novel modulation of structural and functional changes of mouse bone marrow derived dendritic cells (BMDCs) by interleukin-2(IL-2). Hum Vaccin Immunother. 2015; 11(2):516-21. PMC: 4514260. DOI: 10.1080/21645515.2015.1009336. View

15.

Bai Y, Liu R, Huang D, La Cava A, Tang Y, Iwakura Y . CCL2 recruitment of IL-6-producing CD11b+ monocytes to the draining lymph nodes during the initiation of Th17-dependent B cell-mediated autoimmunity. Eur J Immunol. 2008; 38(7):1877-88. DOI: 10.1002/eji.200737973. View

16.

Bikker A, Moret F, Kruize A, Bijlsma J, Lafeber F, van Roon J . IL-7 drives Th1 and Th17 cytokine production in patients with primary SS despite an increase in CD4 T cells lacking the IL-7Rα. Rheumatology (Oxford). 2012; 51(6):996-1005. DOI: 10.1093/rheumatology/ker448. View

17.

Hartgring S, Willis C, Alcorn D, Nelson L, Bijlsma J, Lafeber F . Blockade of the interleukin-7 receptor inhibits collagen-induced arthritis and is associated with reduction of T cell activity and proinflammatory mediators. Arthritis Rheum. 2010; 62(9):2716-25. DOI: 10.1002/art.27578. View

18.

Rihl M, Kellner H, Kellner W, Barthel C, Yu D, Tak P . Identification of interleukin-7 as a candidate disease mediator in spondylarthritis. Arthritis Rheum. 2008; 58(11):3430-5. DOI: 10.1002/art.23998. View

19.

Abdelsadik A, Trad A . Toll-like receptors on the fork roads between innate and adaptive immunity. Hum Immunol. 2011; 72(12):1188-93. DOI: 10.1016/j.humimm.2011.08.015. View

20.

Sela M, Mozes E . The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes. Proc Natl Acad Sci U S A. 2001; 98(22):12642-7. PMC: 60107. DOI: 10.1073/pnas.221456798. View